# Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

> **NCT03993873** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Turning Point Therapeutics, Inc.** · enrollment: 95 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumors
- MET Gene Alterations

## Interventions

- **DRUG:** elzovantinib (TPX-0022)

## Key facts

- **NCT ID:** NCT03993873
- **Lead sponsor:** Turning Point Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-05
- **Primary completion:** 2024-01-08
- **Final completion:** 2027-03-03
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993873, "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03993873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*